Initiative for Access to Healthcare

Despite the rapid progress in technology and knowledge of modern medicine, yet unmet medical needs remain in wide range of therapeutic areas and every R&D-based pharmaceutical company is charged with the mission of addressing these issues by creating innovative new medicines. Furthermore, there are many countries and regions where, people are unable to access equally to adequate medical treatments due to immature medical systems and/or poverty. To solve these issues recognized as Access to Healthcare, we are actively working with governments, international organizations and research institutions, and civil society, as well as through our R&D efforts on innovative medicines.

Basic Policy

The United Nations has officially announced 17 Sustainable Development Goals to be accomplished by 2030 including "Goal 3: Ensure healthy lives and promote well-being for all at all ages," as an applicable agenda on the healthcare.

Contribution to the Achievement of Goal 3 of the SDGs

Our corporate mission is "to broadly contribute to society through value creation based on innovative research and development activities for the betterment of healthcare and fuller lives of people worldwide."
In line with this statement, we will continue to make efforts for Access to Healthcare, through creating innovative new drugs with leading-edge technologies in the focus therapeutic areas of Psychiatry & Neurology, Oncology, and Regenerative medicine/Cell therapy, and providing support for countries and regions where the medical systems need to be improved.

Partnership Initiative "Access Accelerated"

Sumitomo Dainippon Pharma is participating in a partnership initiative "Access Accelerated" as one of the 22 global research-based pharmaceutical companies.
Access Accelerated is a coalition to address non-communicable disease burdens in low and lower-middle income countries. For our individual efforts, we will use a common framework for analyzing to find effective solutions that remove barriers to healthcare.

CEO Commitment

"SDG 3: Ensure healthy lives and promote well-being for all at all ages" is one of the SDGs of the UN, an ambitious goal for one pharmaceutical company to undertake alone. With the commitment of 22 companies, I believe we can take a big step forward toward good health and well-being. To achieve this together and individually, Sumitomo Dainippon Pharma contributes to improving access to healthcare as one of the members of the global pharmaceutical industry. We do this through the continuous creation of innovative pharmaceutical products in the areas of Psychiatry & Neurology and Oncology, which have been designated as the focus therapeutic areas.

Access Accelerated Official website is here.

Masayo Tada
Representative Director,
Sumitomo Dainippon Pharma Co., Ltd.

Initiatives for Access to Healthcare

Global health is a matter of major importance to the Company. We continually support efforts of international stakeholders such as the one described below that strive to improve the healthcare of people around the around.

Provision of Health Education Program for Children and Mothers

Sumitomo Dainippon Pharma is implementing a health-education program for children and mothers in the Kampong Cham District, Cambodia. The company is engaged in initiatives to promote health checkups for infant and pregnant women, regular education and training on nutrition and hygiene, and home-visit childcare support in collaboration with NPO, local governments and communities.

Financial Assistance for Eradication of Malaria

HIV/AIDS, tuberculosis, and malaria, the three major infectious diseases, are global problems that cannot be solved by one country alone but need international cooperation to take steps to address them. Sumitomo Dainippon Pharma supports the initiatives for eradication of malaria in a few countries in Asia and Africa. The company has cooperated with NPOs, local governments and communities to provide insecticide-treated mosquito nets, rapid diagnostic test kits for malaria, and educational activities in Zambia, Tanzania, and Indonesia, as well as advocacy initiatives in Japan.

Financial Assistance for Capacity Building and Patient Advocacy

Sumitomo Dainippon Pharma supports initiatives to improve access to healthcare in developing countries. The company has cooperated with NPOs to implement training and education of nurses in Bangladesh. In Haiti, the company has cooperated with NPOs to implement regular medical examinations for tuberculosis and training of physicians.

Participation in the Global Health Innovative Technology Fund (GHIT Fund)

Sumitomo Dainippon Pharma participates in the Global Health Innovative Technology Fund (GHIT-Fund).
Through our participation, we are seeking to explore how we can utilize our innovative drug discovery technologies for neglected tropical diseases (NTDs), malaria, and other disease fields in which there are significant unmet medical needs, thereby aiming to enhance Access to Health.

Fight against Counterfeit Pharmaceuticals

Illegally manufactured or distributed pharmaceuticals (counterfeit pharmaceuticals) not only provide no therapeutic effects but could pose fatal risks to the patient because of their unknown side effects. The threat is expanding throughout the world in terms of both quantity and the targeted area. The problem of counterfeit pharmaceuticals has another international dimension; their trading could be a lucrative business for organized crimes and international terrorist organizations.

To ensure safety of and trust in our products, we together with peer pharmaceuticals companies join in the initiatives of industrial associations and international organizations and collect and exchange up-to-date information in the fight against counterfeit pharmaceuticals. Specific actions are detailed below.

The Initiatives to Fight against Counterfeit Pharmaceuticals

Membership in PSI: Pharmaceutical Security Institute

As a member of PSI (Pharmaceutical Security Institute), the Company maintains close contact with other global pharmaceutical manufacturers in information gathering and initiating enforcement through appropriate authorities. PSI is a U.S.-based not-for-profit organization founded in 2001. It liaises between pharmaceutical companies and public health authorities and transmits information on counterfeit pharmaceuticals.

Working with INTERPOL to Combat Counterfeit Pharmaceuticals Crimes

Sumitomo Dainippon Pharma is one of 29 global pharmaceutical companies (including eight companies in Japan) that are working together to donate to the International Criminal Police Organization (INTERPOL) a total of 4.5 million Euro over a three-year period beginning in 2013. The donation will be used to fund activities to promote public awareness of counterfeit pharmaceuticals and efforts to prevent pharmaceutical crime, including the training of specialist pharmaceutical crime investigators.

Responding to Demands for Development of Unapproved or Off-Label Drugs

Japan's Ministry of Health, Labour and Welfare (MHLW) invites requests for development of unapproved or off-label drugs that have been approved for use in Europe and the United States but have yet to be approved in Japan. Upon receipt of such a request, MHLW, through a meeting of the Evaluation Committee on Unapproved or Off-Label Drugs with High Medical Needs, evaluates the medical need for the drug concerned and ascertains the validity of clinical studies required to support an application for approval and the drug's eligibility for an Application Based on Public Knowledge, thus promoting the development of such drugs by pharmaceutical manufacturers.

Sumitomo Dainippon Pharma is responding to invitations and requests for development of the following drugs:

Invitation / request for development Product name Indication(s) Development status
2nd round Thiotepa (generic name) - Pretreatment for autologous or allogeneic hematopoietic stem cell transplantation (adults)
- Pretreatment for autologous or allogeneic hematopoietic stem cell transplantation (pediatric)
1st round Amlodin® Additional indication of hypertension in pediatric patients Approved on June 22, 2012
1st round Metgluco® Additional indication of type 2 diabetes in pediatric patients Approved on August 29, 2014